HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dutch Biotech Touts Enzyme-Powered Eczema Cream As ‘Smarter And Safer’ Solution

Executive Summary

Headquartered in The Hague, Netherlands, Micreos is focused on developing targeted antibacterial products to replace antibiotics, protect against food contamination and treat inflammatory skin conditions. The firm’s Gladskin Eczema Cream, now available stateside, uses a patented enzyme technology to destroy Staphylococcus aureus bacteria while leaving skin’s beneficial flora intact.  

You may also be interested in...



L’Oreal’s Microbiome Explorations Lead To Micreos Deal For Next-Gen Antibacterial

“We expect this partnership to be groundbreaking,” says Mark Offerhaus, CEO of Micreos, which will provide L’Oreal with its proprietary endolysin, which selectively destroys microorganisms associated with skin problems while leaving beneficial bacteria intact.

Bayer Harnessing Skin Microbiome In New Product Development

Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions. 

FDA Proposes Priorities For Cosmetic Ingredient Review: Mica, Probiotics, CBD

Nakissa Sadrieh, director of cosmetics at FDA and the agency’s CIR liaison, floated the three potential review priorities at the CIR Expert Panel’s April 8-9 meeting in Washington. It’s the most for-cause targets proposed by the agency in recent memory, and CIR leadership noted that they pose considerable challenges.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel